1. Scrip
  2. >>COVID-19

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

 
• By Joseph Haas

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

Coronavirus globe
Gilead's retrospective analysis of remdesivir needs to be backed up by a traditional study

Gilead Sciences, Inc. is trying to clear up lingering questions about its COVID-19 therapeutic remdesivir with a new retrospective comparative analysis of its SIMPLE-Severe study, including showing a mortality benefit, which had not been evident in data used for global clearances for emergency use of the antiviral. But the select use of data without a controlled trial is drawing criticism.

The Foster City, CA-based company got a small stock bounce on 10 July after releasing retrospective comparative analysis data measuring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.